Autopsy report · NCT04973527

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

“Both the sponsors and collaborator are considering terminating the study”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Beijing Boren Hospital

Sponsor type

University, hospital or other

Conditions

T Cell Lymphoma; T-cell Leukemia

Interventions

Efficacy of LCAR-T2C CAR-T cells

Participants

9

Sites

2

Countries

China

Trials that died the same way

• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (86% match in meaning)
• Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
  “Sponsor decision to terminate the study” (85% match in meaning)
• Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
  “The Sponsor terminated the study.” (84% match in meaning)
• Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
  “The Sponsor chose to terminate this study for commercial reasons.” (82% match in meaning)
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  “This study was terminated by the Sponsor.” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.